Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zasocitinib in Pediatric Participants With Moderate-to-Severe Plaque Psoriasis
NCT07250802Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Dec 2025
- Primary completion
- Jan 2033
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of zasocitinib in plaque psoriasis, sponsored by Takeda. Started Dec 2025; status: recruiting.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07250802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250802.